主页 > 医学动态 >
【medical-news】Entry-Blocking Peptide Inhibits Influenza V
"Our hope is that with further research...on the mechanism of action (of the entry blocker peptide), we could develop an approach to inhibit viral attachment to cells," Dr. Stacey Schultz-Cherry from University of Wisconsin, Madison, told Reuters Health.
Dr. Schultz-Cherry and colleagues investigated the anti-influenza virus activity of a novel peptide they called entry blocker (E, derived from fibroblast growth factor 4 signal sequence, in vivo and in vitro.
EB inhibited influenza virus-induced cell death and replication in cell culture, the authors report, without inducing significant cytotoxicity in the cultured cells.
Pretreatment with EB also improved survival of mice inoculated with influenza virus from 0% to 100%, the results indicate.
Later treatment with a single dose of EB reduced clinical signs of infection and delayed death from influenza virus in similar mice, the researchers note.
EB treatment inhibited viral replication by binding to influenza virus hemagglutinin, thereby preventing attachment of influenza virus to cells, the report indicates.
"As we continue to cope with yearly influenza epidemics and the H5N1 viruses continue to spread, understanding how the viruses interact with cells and developing tools to block this earliest step in viral infection are of enormous public health importance," the investigators state. "The EB peptide has potential as a valuable tool for the study of influenza viruses and their receptor-binding interactions, as well as therapeutic possibilities."
"We have several experiments planned," Dr. Schultz-Cherry said. "First, we want to determine the optimal dose for protection."
The next step will be to "find out how long we can wait post-infection to begin treatment and maintain protection." Finally, they will need to determine "whether prolonged treatment prevents mortality, especially with H5N1 influenza viruses."
J Virol 2006;80:11960-11967.
http://www.medscape.com/viewarticle/550308 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Entry-Blocking Peptide Inhibits Influenza Virus Infection
黏附抑制肽抑制流感病毒感染
NEW YORK (Reuters Health) Jan 04 - A novel peptide that targets viral attachment to cells inhibits influenza virus infection, according to a report in the December issue of the Journal of Virology.
纽约路透社健康版1月4日---一个新的与病毒黏附于细胞作用相关的肽抑制了流感病毒的感染，病毒学杂志在12月份的一篇文章中这样报道。
"Our hope is that with further research...on the mechanism of action (of the entry blocker peptide), we could develop an approach to inhibit viral attachment to cells," Dr. Stacey Schultz-Cherry from University of Wisconsin, Madison, told Reuters Health.
“我们的希望是通过对这个黏附抑制肽作用机理的进一步研究，可以找到抑制流感病毒黏附于细胞的方法”，来自麦迪逊威斯康新大学的Stacey Schultz-Cherry博士这样告诉路透社。
Dr. Schultz-Cherry and colleagues investigated the anti-influenza virus activity of a novel peptide they called entry blocker (E, derived from fibroblast growth factor 4 signal sequence, in vivo and in vitro.
Schultz-Cherry 博士和他的同事研究了这个新肽的抗流感病毒活性，他们称这个肽为黏附抑制肽。（源于成纤维细胞生长因子4的信号序列，在体内和体外）
EB inhibited influenza virus-induced cell death and replication in cell culture, the authors report, without inducing significant cytotoxicity in the cultured cells.
作者报道说，EB 在细胞培养中抑制流感病毒诱导的细胞凋亡和复制，而且没有显著的细胞毒性。
Pretreatment with EB also improved survival of mice inoculated with influenza virus from 0% to 100%, the results indicate.
研究结果表明，经EB 预处理，可以提高流感病毒灌输（0%-100%）小鼠的生存率。
Later treatment with a single dose of EB reduced clinical signs of infection and delayed death from influenza virus in similar mice, the researchers note.
研究者称，单次剂量EB用于延缓治疗，可以在类似的小鼠模型中减轻其感染的临床体征并可以延迟其死亡。
EB treatment inhibited viral replication by binding to influenza virus hemagglutinin, thereby preventing attachment of influenza virus to cells, the report indicates.
报道还指出，EB治疗是通过与流感病毒血凝素结合，抑制病毒复制，从而阻止了流感病毒与细胞的黏附。
"As we continue to cope with yearly influenza epidemics and the H5N1 viruses continue to spread, understanding how the viruses interact with cells and developing tools to block this earliest step in viral infection are of enormous public health importance," the investigators state. "The EB peptide has potential as a valuable tool for the study of influenza viruses and their receptor-binding interactions, as well as therapeutic possibilities."
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-26 17:11
医学,生命科学网